Eli Lilly and Company (LLY) Stock Analysis
Last updated Sep 8, 2026
Health Check
Last analyzed Sep 7, 2026
- Financial Health 65
- Profitability 100
- Business Quality 100
- Balance Sheet 55
- Cash Flow 80
Why this rating?
Health 86/100 — Elite Quality
Worth tracking, but timing is mixed — not a clear setup yet.
Company overview
Eli Lilly and Company (LLY) is a Drug Manufacturers - General company in the Healthcare sector. Compound Radar rates Eli Lilly and Company 86/100 (Elite Quality) due to high business quality, strong revenue growth, and manageable leverage.
Investment profile
- Quality High
- Growth Strong
- Balance Sheet Adequate
- Valuation Fair
Financial highlights
Valuation
- P/E 37.75
- Forward P/E 23.78
- PEG 1.11
- EV/Revenue 13.44
Profitability
- Revenue Growth 47.7%
- Gross Margin 83.4%
- Operating Margin 54.2%
- Net Margin 33.5%
- ROE 102.3%
Financial strength
- Cash $8.95B
- Debt $54.91B
- Net Cash $-45.96B
- Free Cash Flow $5.96B
- Current Ratio 1.36
Similar companies
Peers in Drug Manufacturers - General, ranked by Financial Health.
Latest quoted price for the name. Helps anchor the setup in today’s market level.
Health Entry- AstraZeneca PLC Drug Manufacturers - General AZN$160.04 74 Health 74 / 100
Strong business quality across profitability, growth, balance sheet, and cash flow.
Wait WaitEntry timing is weak right now. Quality may be fine; the setup is not.
- Gilead Sciences, Inc. Drug Manufacturers - General GILD$146.64 74 Health 74 / 100
Strong business quality across profitability, growth, balance sheet, and cash flow.
Watch WatchWorth tracking, but timing is mixed — not a clear setup yet.
- Biogen Inc. Drug Manufacturers - General BIIB$212.50 74 Health 74 / 100
Strong business quality across profitability, growth, balance sheet, and cash flow.
Wait WaitEntry timing is weak right now. Quality may be fine; the setup is not.
- AbbVie Inc. Drug Manufacturers - General ABBV$248.78 73 Health 73 / 100
Strong business quality across profitability, growth, balance sheet, and cash flow.
Watch WatchWorth tracking, but timing is mixed — not a clear setup yet.
- Bristol-Myers Squibb Company Drug Manufacturers - General BMY$64.69 72 Health 72 / 100
Strong business quality across profitability, growth, balance sheet, and cash flow.
Watch WatchWorth tracking, but timing is mixed — not a clear setup yet.
- Johnson & Johnson Drug Manufacturers - General JNJ$269.12 71 Health 71 / 100
Strong business quality across profitability, growth, balance sheet, and cash flow.
Wait WaitEntry timing is weak right now. Quality may be fine; the setup is not.
- Pfizer Inc. Drug Manufacturers - General PFE$27.79 71 Health 71 / 100
Strong business quality across profitability, growth, balance sheet, and cash flow.
Wait WaitEntry timing is weak right now. Quality may be fine; the setup is not.
- Amgen Inc. Drug Manufacturers - General AMGN$393.17 68 Health 68 / 100
Solid fundamentals with some trade-offs across our health dimensions.
Wait WaitEntry timing is weak right now. Quality may be fine; the setup is not.
FAQ
How Compound Radar scores and tracks Eli Lilly and Company (LLY).